Late last week, President Donald Trump sent letters to 17 pharmaceutical companies pressing them to deliver on his May Executive Order 14297, titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.” Trump gave the companies 60 days to extend Most Favored Nation (MFN) pricing to all Medicaid patients, for newly launched drugs, to return increased revenues from negotiations with countries to American patients, and to provide for direct purchasing options to patients at MFN rates.
Recent Posts
- CAFC Majority Reverses PTAB Obviousness Ruling Over Dissent, But Rule 36 Issues Persist for CPC Patent
- Liability Risks Before the UPC: How U.S. Companies Need to Prepare
- Other Barks & Bites for Friday, November 7: CJEU Action Against EU Commission Referred Over SEP Regulation; Ninth Circuit Affirms CoComelon Copyright Win; and C4IP Urges USTR to Address IP Concerns in USMCA Joint Review
- Mixed UK High Court Ruling Fails to Answer Fundamental Questions of AI Copyright Infringement
- Professors Press SCOTUS to Affirm Copyright Protection for AI-Created Works